Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 5/20 | 0.53 |
| ▸ | OPRD1 | P41143 | 5/20 | 0.53 |
| ▸ | CALCRL | Q16602 | 4/20 | 0.50 |
| ▸ | RAMP1 | O60894 | 1/20 | 0.49 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.47 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | APLNR | P35414 | 1/20 | 0.46 |
| ▸ | BDKRB2 | P30411 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30011949 | 0.89 | CALCRL (0.51) | OPRM1OPRD1CALCRLRAMP1SLC6A2 | |
| SCHEMBL31294857 | 0.86 | ACE (0.52) | OPRM1OPRD1CALCRLRAMP1 | |
| SCHEMBL31598479 | 0.84 | APLNR (0.56) | OPRM1OPRD1APLNR | |
| SCHEMBL31598486 | 0.84 | APLNR (0.56) | OPRM1OPRD1APLNR | |
| SCHEMBL30992045 | 0.84 | OPRM1 (0.51) | OPRM1OPRD1SLC6A2 | |
| SCHEMBL29579716 | 0.83 | CALCRL (0.61) | OPRM1OPRD1CALCRLRAMP1SLC6A2 | |
| SCHEMBL30503065 | 0.83 | OPRD1 (0.60) | OPRM1OPRD1SLC6A2 | |
| SCHEMBL31596986 | 0.82 | OPRM1 (0.64) | OPRM1OPRD1SLC6A2OPRK1BDKRB2 | |
| SCHEMBL31596868 | 0.82 | OPRM1 (0.64) | OPRM1OPRD1SLC6A2OPRK1BDKRB2 | |
| SCHEMBL29579417 | 0.82 | CALCRL (0.62) | CALCRLRAMP1SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12618102-B2 | Biochemical reaction methods and reagents comprising intrinsically disordered regions | Biocrucible Limited (GB) | 2026-05-05 | — | — | US | disclosed |
| US-20220112547-A1 | BIOCHEMICAL REACTION METHODS AND REAGENTS COMPRISING INTRINSICALLY DISORDERED REGIONS | Biocrucible Limited (GB) | 2022-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12618102-B2 | Biochemical reaction methods and reagents comprising intrinsically disordered regions | POLM, POLR1A, POLR1E | OPRM1 4101/4885OPRD1 4566/4885CALCRL 1768/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.